



News Release

Pivotal Therapeutics Inc. Opens United States Commercialization and Distribution Headquarters

FOR IMMEDIATE RELEASE

June 2, 2011

Boca Raton, Florida, June 2, 2011 - Pivotal Therapeutics Inc. (CNSX:PVO) announces the opening of its U.S. headquarters at the Research Park at Florida Atlantic University (FAU).

The U.S. location will focus upon the commercialization and product distribution of its lead cardiovascular product VASCAZEN™.

"We specifically chose the Research Park at FAU because it is strategically located at the epicenter of Florida's burgeoning biotechnology corridor," stated Dr. George Jackowski, Pivotal Therapeutics Chairman and Chief Scientific Officer.

The Florida Atlantic Research Park is the only university related Research Park in South Florida. Located adjacent to the main campus of Florida Atlantic University, the Park is in close proximity to Scripps Florida, Torrey Pines Institute for Molecular Studies, the University of Miami Miller School of Medicine, the world-renowned Harbor Branch Research Center, as well as being almost midway between FIU and UCF. "The Research Park at FAU is committed to supporting innovative businesses. We are delighted that Pivotal Therapeutics has moved to the park and will continue to grow and develop its business here," said Andrew Duffell, President/CEO of the Florida Atlantic Research & Development Authority.

Pivotal Therapeutics will join other like-minded companies in the Technology Business Incubator, located at the Research Park's Boca Raton campus. "Being around the other entrepreneurial ventures at the Park will provide opportunities to additional research and development, creating more opportunity for students and faculty to interact with cutting edge commercial ventures," added Duffell.

"Pivotal's long-term goals of continuing to develop cutting edge medical foods for the treatment and management of cardiovascular diseases should benefit greatly from our ability to enter into collaborative research and development agreements with the fine institutions available to us in South Florida," said Jackowski.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (CNSX: PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease. Pivotal Therapeutics' lead product VASCAZEN™ is a prescription medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.

VASCAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.

About Florida Atlantic Research and Development Authority (FARDA)

The Florida Atlantic Research and Development Authority, (www.research-park.org), is the governing body for the Research Park at FAU, including the main park in Boca Raton on the north side of the Florida



Atlantic University campus and a second campus on I-95 in Deerfield Beach. FARDA was established by the Broward and Palm Beach county commissions to create and sustain research parks in both counties.

About the Research Park at FAU

Established in 1985, the 94-acre Research Park is home to 26 mature technology companies working in conjunction with the FAU College of Engineering and Computer Science, the FAU Charles E. Schmidt College of Medicine and the FAU Adams Center for Entrepreneurship. The Research Park hosts the Technology Business Incubator with 25 startup technology companies, each of which receives business and consulting services, with the goal of becoming established businesses and permanent residents of the Research Park. Also located at the Park are the New World Angels, a structured investor group, and the Institute for the Commercialization of Public Research, a clearinghouse for technology transfers in Florida.

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include, our inability to obtain additional financing on acceptable terms, risk that our products and services will not gain widespread market acceptance; continued consumer adoption of digital technology, inability to compete with others who provide comparable products, the failure of our technology, inability to respond to consumer and technological demands, inability to replace significant customers; seasonal nature of our business and other risks detailed in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.

-#-

Contact:

Rachelle Mac Sweeney
President

Phone
E-Mail

905-856-9797
rmacsweeney@pivotaltherapeutics.us

Pivotal Therapeutics Inc.

www.pivotaltherapeutics.us
